Triflusal
CAS No. 322-79-2
Triflusal( Triflusal, Disgren, Grendis, Aflen, Triflux )
Catalog No. M14050 CAS No. 322-79-2
Triflusal is a platelet aggregation inhibitor that was discovered and developed in the Uriach Laboratories, and commercialised in Spain since 1981.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 41 | In Stock |
|
| 5MG | 37 | In Stock |
|
| 10MG | 49 | In Stock |
|
| 25MG | 73 | In Stock |
|
| 50MG | 91 | In Stock |
|
| 100MG | 126 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | 230 | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameTriflusal
-
NoteResearch use only, not for human use.
-
Brief DescriptionTriflusal is a platelet aggregation inhibitor that was discovered and developed in the Uriach Laboratories, and commercialised in Spain since 1981.
-
DescriptionTriflusal is a platelet aggregation inhibitor that was discovered and developed in the Uriach Laboratories, and commercialised in Spain since 1981. Currently, it is available in 25 countries in Europe, Asia, Africa and America. It is a drug of the salicylate family but it is not a derivative of acetylsalicylic acid (ASA).
-
In Vitro——
-
In Vivo——
-
SynonymsTriflusal, Disgren, Grendis, Aflen, Triflux
-
PathwayAngiogenesis
-
TargetPDE
-
RecptorPDE| TXA2R
-
Research AreaInflammation/Immunology
-
Indication——
Chemical Information
-
CAS Number322-79-2
-
Formula Weight248.16
-
Molecular FormulaC10H7F3O4
-
Purity>98% (HPLC)
-
SolubilityEthanol: 50 mg/mL (201.48 mM); DMSO: 50 mg/mL (201.48 mM)
-
SMILESO=C(O)C1=CC=C(C(F)(F)F)C=C1OC(C)=O
-
Chemical Name2-acetyloxy-4-(trifluoromethyl)benzoic acid
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Acta Crystallographica Section A, 49 ( Pt 1), 10-22 (1993)
molnova catalog
related products
-
PDE9-IN-(S)-C33
PDE9-IN-(S)-C33 is a potent and selective inhibitor of PDE9 (IC50 = 11 nM). PDE9-IN-(S)-C33 can be used for central nervous system diseases and diabetes research.
-
MR-L2
MR-L2 is a reversible and noncompetitive allosteric activator of long-isoform phosphodiesterase-4 (PDE4).
-
Cilomilast
A potent and selective PDE4 inhibitor with IC50 of 95/120 nM for LPDE4/HPDE4.
Cart
sales@molnova.com